pediatric acute myeloid leukemia
H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations
89
Dexamethasone in hyperleukocytic acute myeloid leukemia
12
Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the LEA program
5
Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia
19
Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3‐ITD‐driven acute myeloid leukemia
24
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
12
ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
8
Prophylactic donor lymphocyte infusion in patients with high-risk acute myeloid leukemia: ready for prime time?
3
The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs
10
Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143)
14
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
10
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
34
A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
8
Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission
7
Practical management of Chronic Myeloid Leukemia in Belgium
17
Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia
14
Understanding the transcriptional control of EIF4E and its dysregulation in acute myeloid leukemia: role of NF-κB
154
Acute lymphoblastic leukemia in children
7
Survival improvement of secondary acute myeloid leukemia over time: experience from 962 patients included in 13 EORTC-Gimema-HOVON leukemia group trials
3
Caractérisation de l'oncogène MLF1 (Myeloid Leukemia Factor 1)
116